Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for ...

Opens in a new tab or window For medical teams tasked with caring for patients with diffuse large B-cell lymphoma, progression or relapse that involves the central nervous system can be extremely ...

Diffuse Large B-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive ...

Adcetris is also indicated as monotherapy or in combination with chemotherapy for the treatment of certain types of classical Hodgkin lymphoma, anaplastic large cell lymphoma and peripheral T-cell ...

(2:51) For medical teams tasked with caring for patients with diffuse large B-cell lymphoma, progression or relapse that involves the central nervous system can be extremely challenging and ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance ...

Columvi plus chemotherapy showed a 41% reduction in the risk of death in the pivotal phase III STARGLO study 1,2 ; DLBCL-an ...

NICE's initial guidance on Breyanzi concluded it was not a cost-effective option for patients, but the agency said this ...

During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...

The company will push through with an accelerated approval application for odronextamab in follicular lymphoma, leaving ...

CAR T-cell therapy showed efficacy in relapsed large B-cell lymphoma across age groups, including patients 70 and 80 years or older.

Researchers Identify Key Characteristics Associated With Improved CAR T Outcomes in Large B Cell Lymphoma Jan. 17, 2024 — Axi-cel CAR T targets the CD19 molecule on large B-cell lymphoma cells.